Explore our certified commercial-grade Active Pharmaceutical Ingredients (APIs), key metabolic intermediates, and specialized fine chemicals produced under rigorous international compliance standards.
Orlistat (CAS 96829-58-2), chemically designated as (S)-((S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl) 2-formamido-4-methylpentanoate, represents the premier potent, specific, and long-acting gastrointestinal lipase inhibitor recognized by worldwide regulatory authorities including the US FDA, EMA, and NMPA. Unlike systemic anti-obesity agents that act upon the central nervous system, Orlistat exerts its therapeutic efficacy locally within the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of gastric and pancreatic lipases.
From a chemical manufacturing perspective, Orlistat is a saturated derivative of lipstatin, a natural metabolite isolated from the actinobacterium Streptomyces toxytricini. The chemical structure features a reactive β-lactone ring system critical for its irreversible pharmacological activity. In commercial pharmaceutical synthesis, obtaining high-purity Orlistat requires precise control over stereogenic centers to eliminate unwanted diastereomeric impurities, ensuring strict compliance with USP, EP, and JP pharmacopeial standards.
| Parameter | Pharmacopeial Requirement (USP / EP) | Gentolex High-Purity Commercial Grade | Analytical Method |
|---|---|---|---|
| Chemical Formula | C29H53NO5 | C29H53NO5 (MW: 495.73 g/mol) | Mass Spectrometry (MS) |
| Appearance | White to off-white crystalline powder | White crystalline powder / Free-flowing micro-pellets | Visual Inspection |
| Assay (Drying Basis) | 98.0% - 101.5% | 99.2% - 100.8% | HPLC (External Standard) |
| Stereochemical / Chiral Purity | Diastereomers ≤ 0.5% | Diastereomers ≤ 0.15% | Chiral HPLC |
| Melting Point | 43.0°C to 48.0°C | 44.5°C to 46.5°C | Differential Scanning Calorimetry (DSC) |
| Residual Solvents | Meets ICH Q3C Limits | Ethanol < 500ppm, Acetone < 200ppm (Ultra-low) | Headspace Gas Chromatography (HS-GC) |
| Heavy Metals / Elemental Impurities | Meets ICH Q3D Limits | Total Heavy Metals < 10 ppm, Lead < 0.5 ppm | ICP-MS |
The global market for metabolic disorders and weight management therapeutics is undergoing a unprecedented paradigm shift. While injectable peptide therapies such as GLP-1 receptor agonists (e.g., Semaglutide, Tirzepatide, Retatrutide) dominate headlines, oral small-molecule interventions like Orlistat (96829-58-2) continue to command a crucial, non-substitutable segment of the global market.
Orlistat remains the only non-systemic anti-obesity agent granted Over-The-Counter (OTC) status across major markets including North America, Europe, and Asia-Pacific (at 60mg dosage formulations). The rising incidence of metabolic syndrome in developing economies drives explosive OTC consumer demand due to affordability and lack of required prescription barriers.
Modern clinical research highlights the synergistic potential of combining gastrointestinal fat-absorption blockade (Orlistat) with systemic appetite-regulating peptides or dietary fiber formulations. Post-injection maintenance regimens increasingly incorporate Orlistat to prevent body weight rebound following GLP-1 therapy discontinuation.
Traditional multi-step chemical extraction processes are rapidly being replaced by eco-friendly semi-synthetic and biocatalytic routes. Advanced fermentation of Streptomyces precursors coupled with enzymatic stereoselective hydrogenations reduce solvent consumption by up to 40% and yield higher purity batch outputs.
For pharmaceutical procurement managers, quality control directors, and brand owners, securing a reliable supply of CAS 96829-58-2 Orlistat requires rigorous technical vetting. The low melting point of Orlistat (44°C–46°C) presents unique stability and formulation challenges that only advanced chemical manufacturing plants can reliably control.
We provide comprehensive regulatory dossiers and testing validation packages to accelerate market registration worldwide:
As global pharmaceutical procurement demands greater supply chain transparency, cost optimization, and risk mitigation, Gentolex Group leverages state-of-the-art Industry 4.0 automation across its massive manufacturing footprint. Our smart infrastructure integrates real-time process analytical technology (PAT) with automated solvent recovery and closed-loop chemical containment.
An overall standard factory construction area of 250,000 square meters designed under strict international cGMP standards to offer flexible, scalable, and highly cost-effective manufacturing solutions from multi-kilogram pilot batches to multi-ton commercial production.
Gentolex secures continuous end-to-end supply chain control by directly synthesizing key starting materials (KSMs) and precursors internally. This strategic backward integration insulates global buyers from raw material price volatility and geopolitical supply bottlenecks.
With satisfied clients across more than 10 countries and dedicated regional representatives established in Mexico and South Africa, Gentolex bridges international language, timezone, and regulatory differences to provide seamless supply chain logistics.
The therapeutic versatility of CAS 96829-58-2 Orlistat extends across multiple oral solid dosage formats. Formulators must address Orlistat’s low melting point, hydrophobic surface, and tendency to adhere to equipment punch faces during compression.
The industry gold-standard dosage form utilizes extrusion-spheronization to form high-density Orlistat pellets coated with microcrystalline cellulose and sodium starch glycolate. Encapsulation into hard gelatin or HPMC capsules ensures rapid dispersion within gastric fluids for maximum enzymatic binding upon meal ingestion.
Modern consumer-friendly formulations leverage co-processed excipient binder networks to create chewable Orlistat formats. Gentolex supplies specialized free-flowing micronized API tailored to minimize mouth-feel grittiness and enable smooth taste-masking matrix integration.
Innovative nutraceutical and pharma formulations pair Orlistat with fat-soluble vitamin complexes (Vitamins A, D, E, K) or lipophilic nutrient carriers to offset potential fat-soluble nutrient malabsorption, optimizing long-term patient compliance.
Beyond raw API supply, Gentolex offers finished dosage form (FDF) licensing out packages, technology transfer protocols, product line design, and specialized analytical lab setups for pharmaceutical manufacturers seeking rapid market entry.
Gentolex’s overarching mission is to create unprecedented global opportunities connecting pharmaceutical researchers and manufacturers with superior services and guaranteed chemical products. To date, Gentolex Group serves satisfied enterprise clients across more than 10 countries, supported by established international representatives in Mexico and South Africa.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations.
High-purity peptide API synthesis, side-chain protection, custom sequence modifications, and research-grade peptide manufacturing.
For clients seeking to avoid multi-vendor complexity, we provide end-to-end customized procurement services backed by our robust supply chain network.
Stay updated with the latest technological developments in peptide synthesis, active pharmaceutical ingredient innovations, and market trends.
Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro...
View Details
As a professional Thymosin Beta-4 API manufacturer, we provide high-quality Tβ4 peptide API solutions for biotech companies and clinical research...
View Details
BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities...
View Details
Semax, a synthetic peptide derived from an ACTH fragment, has attracted attention among researchers due to its unique neuroactive properties...
View Details
SS-31 API, also known as Elamipretide, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane...
View DetailsDetailed technical answers to common questions raised by pharmaceutical formulation scientists, quality auditors, and global B2B buyers.
Browse additional active pharmaceutical ingredients, protected amino acids, and custom peptides from Gentolex’s global manufacturing pipeline.
Connect directly with Gentolex Group's technical API sales directors. Request technical dossiers, sample quantities, customized particle size specifications, or factory audit schedules today.
